Etiology and Outcome of Crescentic Glomerulonephritis From a Single Center in China: A 10-Year Review

医学 狼疮性肾炎 肾小球肾炎 膜性肾病 肾脏疾病 肾病 肾活检 胃肠病学 肾小球基底膜 内科学 单中心 病理 血清学 肾炎 活检 免疫学 抗体 疾病 内分泌学 糖尿病
作者
Shasha Chen,Zheng Tang,Hao Xiang,Xiaowei Li,Hao Chen,Haitao Zhang,Weixin Hu,Caihong Zeng,Zhihong Liu
出处
期刊:American Journal of Kidney Diseases [Elsevier]
卷期号:67 (3): 376-383 被引量:49
标识
DOI:10.1053/j.ajkd.2015.07.034
摘要

Background The disease spectrum of crescentic glomerulonephritis (GN) has been described in only a few previous studies, and detailed epidemiologic data from China are unavailable to date. Study Design Case series. Setting & Participants 528 patients with biopsy-proven crescentic GN in 2003 to 2013 from a single center. Predictor Crescentic GN was classified into 3 types according to immunofluorescence findings: type I was defined as linear deposition of immunoglobulins along the glomerular basement membrane; type II, as glomerular deposition of immune complex; and type III, as pauci-immune deposition. Outcomes Demographic, clinical, and serologic characteristics. Results Of 528 cases identified, 208 (39.4%) were men, with a mean age of 37.6 ± 16.4 (SD) years at kidney biopsy. 61 (11.6%) patients had type I crescentic GN, 331 (62.7%) had type II (lupus nephritis, 34.3%; immunoglobulin A [IgA] nephropathy, 17.4%), and 136 (25.8%) had type III. Proportions of patients with acute kidney injury (AKI), acute kidney diseases and disorders without AKI, and chronic kidney disease were 86.9%, 0%, and 13.1% for type I; 42.0%, 19.6%, and 38.4% for type II; and 84.6%, 2.9%, and 12.5% for type III crescentic GN, respectively. Serum antineutrophil cytoplasmic antibodies were detected in 11 (18.0%) patients with type I, 15 (4.5%) with type II, and 117 (86.0%) with type III. Anti–glomerular basement membrane antibodies were found in 60 (98.4%) patients with type I, 3 (0.9%) with type II, and 5 (3.7%) with type III. 5-year cumulative renal survival rates for patients with types I, II, and III were 17.6%, 70.1%, and 44.3%, respectively. Limitations Retrospective study, single-center experience. Conclusions Lupus nephritis may be the most common type of crescentic GN in China, followed by pauci-immune crescentic GN and IgA nephropathy. Almost half the patients presented with AKI, whereas 28.8% of cases showed chronic kidney disease. Clinical manifestations and outcomes varied according to crescentic GN type. The distinction between subtypes based on immunofluorescence and serologic findings has important implications for therapy and outcome. The disease spectrum of crescentic glomerulonephritis (GN) has been described in only a few previous studies, and detailed epidemiologic data from China are unavailable to date. Case series. 528 patients with biopsy-proven crescentic GN in 2003 to 2013 from a single center. Crescentic GN was classified into 3 types according to immunofluorescence findings: type I was defined as linear deposition of immunoglobulins along the glomerular basement membrane; type II, as glomerular deposition of immune complex; and type III, as pauci-immune deposition. Demographic, clinical, and serologic characteristics. Of 528 cases identified, 208 (39.4%) were men, with a mean age of 37.6 ± 16.4 (SD) years at kidney biopsy. 61 (11.6%) patients had type I crescentic GN, 331 (62.7%) had type II (lupus nephritis, 34.3%; immunoglobulin A [IgA] nephropathy, 17.4%), and 136 (25.8%) had type III. Proportions of patients with acute kidney injury (AKI), acute kidney diseases and disorders without AKI, and chronic kidney disease were 86.9%, 0%, and 13.1% for type I; 42.0%, 19.6%, and 38.4% for type II; and 84.6%, 2.9%, and 12.5% for type III crescentic GN, respectively. Serum antineutrophil cytoplasmic antibodies were detected in 11 (18.0%) patients with type I, 15 (4.5%) with type II, and 117 (86.0%) with type III. Anti–glomerular basement membrane antibodies were found in 60 (98.4%) patients with type I, 3 (0.9%) with type II, and 5 (3.7%) with type III. 5-year cumulative renal survival rates for patients with types I, II, and III were 17.6%, 70.1%, and 44.3%, respectively. Retrospective study, single-center experience. Lupus nephritis may be the most common type of crescentic GN in China, followed by pauci-immune crescentic GN and IgA nephropathy. Almost half the patients presented with AKI, whereas 28.8% of cases showed chronic kidney disease. Clinical manifestations and outcomes varied according to crescentic GN type. The distinction between subtypes based on immunofluorescence and serologic findings has important implications for therapy and outcome.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
靡初完成签到 ,获得积分10
刚刚
1秒前
Astro完成签到,获得积分10
2秒前
2秒前
keiiin完成签到,获得积分10
2秒前
桐桐应助枫树狐狸采纳,获得10
2秒前
2秒前
lxshu0722发布了新的文献求助10
2秒前
2秒前
孝择发布了新的文献求助10
3秒前
3秒前
zhu发布了新的文献求助10
3秒前
3秒前
young完成签到,获得积分10
3秒前
月白发布了新的文献求助10
3秒前
5EN发布了新的文献求助10
3秒前
bkagyin应助tangxinhebaodan采纳,获得10
4秒前
4秒前
xh发布了新的文献求助10
4秒前
方人也关注了科研通微信公众号
4秒前
希望天下0贩的0应助ming采纳,获得10
4秒前
靡初关注了科研通微信公众号
5秒前
子车茗应助yyy采纳,获得20
5秒前
5秒前
6秒前
Astro发布了新的文献求助10
6秒前
6秒前
一米八发布了新的文献求助10
7秒前
sxpab发布了新的文献求助10
7秒前
8秒前
麒麟发布了新的文献求助10
8秒前
科研通AI6.3应助隐形刺猬采纳,获得10
8秒前
凡子鸣完成签到,获得积分10
8秒前
LethNefli发布了新的文献求助10
8秒前
阿哈发布了新的文献求助10
9秒前
科研通AI6.2应助liumenghan采纳,获得30
9秒前
小巧尔岚完成签到,获得积分10
9秒前
jiao完成签到 ,获得积分10
10秒前
Maestro_S发布了新的文献求助10
10秒前
识字岭的岭应助sonia0720采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Relation between chemical structure and local anesthetic action: tertiary alkylamine derivatives of diphenylhydantoin 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Principles of town planning : translating concepts to applications 500
Iron‐Sulfur Clusters: Biogenesis and Biochemistry 400
Healable Polymer Systems: Fundamentals, Synthesis and Applications 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6069912
求助须知:如何正确求助?哪些是违规求助? 7901770
关于积分的说明 16335059
捐赠科研通 5210839
什么是DOI,文献DOI怎么找? 2787111
邀请新用户注册赠送积分活动 1769917
关于科研通互助平台的介绍 1648020